{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:34:13Z","timestamp":1790721253459,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.iac.2025.04.008","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T23:29:05Z","timestamp":1750116545000},"page":"419-427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Emerging Role of Novel Therapeutics"],"prefix":"10.1016","volume":"45","author":[{"given":"Sayantani B.","family":"Sindher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eimear","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Sharon","family":"Chinthrajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iac.2025.04.008_bib1","unstructured":"FDA US, FDA approves first medication to help reduce allergic reactions to multiple foods after accidental exposure, 2024, US FDA, Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-medication-help-reduce-allergic-reactions-multiple-foods-after-accidental."},{"key":"10.1016\/j.iac.2025.04.008_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2023.04.023","article-title":"Treatment of food allergy: oral immunotherapy, biologics, and beyond","author":"Sindher","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.iac.2025.04.008_bib4","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/cea.13897","article-title":"The use of biologics in food allergy","volume":"51","author":"Fiocchi","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"10.1016\/j.iac.2025.04.008_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12072699","article-title":"Emerging role of alarmins in food allergy: an update on pathophysiological insights, potential use as disease biomarkers, and therapeutic implications","volume":"12","author":"Rizzi","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.iac.2025.04.008_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2023.01.007","article-title":"The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders","volume":"151","author":"Sindher","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"16","key":"10.1016\/j.iac.2025.04.008_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172335","article-title":"A phase II study of Bruton\u2019s tyrosine kinase inhibition for the prevention of anaphylaxis","volume":"133","author":"Suresh","year":"2023","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.iac.2025.04.008_bib8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2165\/00063030-200216050-00009","article-title":"Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25","volume":"16","year":"2002","journal-title":"BioDrugs"},{"key":"10.1016\/j.iac.2025.04.008_bib9","article-title":"Protocol design and synopsis: omalizumab as monotherapy and as adjunct therapy to multiallergen OIT in children and adults with food allergy (OUtMATCH)","author":"Wood RSC","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2025.04.008_bib10","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.iac.2025.04.008_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2020.111831","article-title":"Full range of population eliciting dose values for 14 priority allergenic foods and recommendations for use in risk characterization","volume":"146","author":"Houben","year":"2020","journal-title":"Food Chem Toxicol"},{"issue":"2","key":"10.1016\/j.iac.2025.04.008_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.11.909","article-title":"Omalizumab for the treatment of multiple food allergy (OUtMATCH)","volume":"153","author":"Wood","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2025.04.008_bib13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2025.04.008_bib14","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/cea.13469","article-title":"Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents","volume":"49","author":"Brandstrom","year":"2019","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.iac.2025.04.008_bib15","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow\u2019s milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2025.04.008_bib16","article-title":"Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis","author":"Zuberbier","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.iac.2025.04.008_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.iac.2025.04.008_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eclinm.2018.12.006","article-title":"A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals","volume":"7","author":"Andorf","year":"2019","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.iac.2025.04.008_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1710-1492-10-7","article-title":"Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab","volume":"10","author":"Begin","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"6","key":"10.1016\/j.iac.2025.04.008_bib20","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2019.01.023","article-title":"Impact of omalizumab on food allergy in patients treated for asthma: a real-life study","volume":"7","author":"Fiocchi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.iac.2025.04.008_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100690","article-title":"The rationale for development of ligelizumab in food allergy","volume":"15","author":"Wood","year":"2022","journal-title":"World Allergy Organ J"},{"issue":"1","key":"10.1016\/j.iac.2025.04.008_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.iac.2025.04.008_bib23","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1111\/all.14308","article-title":"Past, present, and future of anti-IgE biologics","volume":"75","author":"Guntern","year":"2020","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.iac.2025.04.008_bib24","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.iac.2025.04.008_bib25","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jaci.2016.02.027","article-title":"Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses","volume":"138","author":"Gauvreau","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2025.04.008_bib26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2174\/187221310793564281","article-title":"Current prospective of anti-IL-4, -IL-9, and -IL-13 therapies in allergic disease","volume":"4","author":"Steinke","year":"2010","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"10.1016\/j.iac.2025.04.008_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.12703\/r\/10-71","article-title":"Recent advances in understanding the role of IL-4 signaling","volume":"10","author":"Keegan","year":"2021","journal-title":"Fac Rev"},{"issue":"2","key":"10.1016\/j.iac.2025.04.008_bib28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaip.2018.07.027","article-title":"Dupilumab for treatment of food allergy","volume":"7","author":"Rial","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.iac.2025.04.008_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12381","article-title":"Dupilumab induces a significant decrease of food specific immunoglobulin E levels in pediatric atopic dermatitis patients","volume":"14","author":"van der Rijst","year":"2024","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.iac.2025.04.008_bib30","article-title":"Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients","author":"Spekhorst","year":"2022","journal-title":"Allergy"},{"issue":"16","key":"10.1016\/j.iac.2025.04.008_bib31","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.3390\/nu16162797","article-title":"Dupilumab as therapeutic option in polysensitized atopic dermatitis patients suffering from food allergy","volume":"16","author":"Sernicola","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.iac.2025.04.008_bib32","article-title":"Efficacy and safety of dupilumab in children with peanut allergy: a multicenter, open-label, phase II study","author":"Sindher","year":"2024","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.iac.2025.04.008_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13935","article-title":"Delayed-type hypersensitivity gastrointestinal symptoms induced by food oral immunotherapy and efficiently treated by dupilumab: a case report","volume":"34","author":"Braun","year":"2023","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.iac.2025.04.008_bib34","article-title":"Dupilumab to induce tolerance to SLIT-Melocoton(R)","author":"Zamarro","year":"2023","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2025.04.008_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18176\/jiaci.0355","article-title":"Immune basis of allergic reactions to food","volume":"29","author":"Lozano-Ojalvo","year":"2019","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"22","key":"10.1016\/j.iac.2025.04.008_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.iac.2025.04.008_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.12.916","article-title":"Administration of two doses of an oral, irreversible inhibitor of Bruton\u2019s tyrosine kinase (BTK) to food allergic adults abrogates skin test responses and eliminates IgE-mediated basophil activation ex vivo","volume":"141","author":"Dispenza","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2025.04.008_bib38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40521-021-00286-y","article-title":"The use of Bruton\u2019s tyrosine kinase inhibitors to treat allergic disorders","volume":"8","author":"Dispenza","year":"2021","journal-title":"Curr Treat Options Allergy"},{"issue":"5","key":"10.1016\/j.iac.2025.04.008_bib39","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.jaci.2017.12.987","article-title":"Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy","volume":"141","author":"Dispenza","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2025.04.008_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.anai.2024.03.002","article-title":"Bruton\u2019s tyrosine kinase inhibition for the treatment of allergic disorders","volume":"133","author":"Lin","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"10.1016\/j.iac.2025.04.008_bib41","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1172\/JCI138448","article-title":"Bruton\u2019s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis","volume":"130","author":"Dispenza","year":"2020","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1016\/j.iac.2025.04.008_bib42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/ACI.0000000000000981","article-title":"New biologics for food allergy","volume":"24","author":"Schuetz","year":"2024","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856125000293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856125000293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:29:02Z","timestamp":1752593342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856125000293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0889856125000293"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2025.04.008","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Role of Novel Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2025.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}